# EDGAR Filing Document

**Accession Number:** 0001754195
**File Stem:** 0001754195-26-000005
**Filing Date:** 2026-1
**Character Count:** 19182
**Document Hash:** e1b3672072534eb304288adf419a4648
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001754195-26-000005.hdr.sgml**: 20260129

**ACCESSION NUMBER**: 0001754195-26-000005

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260129

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260129

**DATE AS OF CHANGE**: 20260129

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Trulieve Cannabis Corp.
- **CENTRAL INDEX KEY:** 0001754195
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 581882476
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56248
- **FILM NUMBER:** 26574965

**BUSINESS ADDRESS:**
- **STREET 1:** 6749 BEN BOSTIC ROAD
- **CITY:** QUINCY
- **STATE:** FL
- **ZIP:** 32351
- **BUSINESS PHONE:** 8502988866

**MAIL ADDRESS:**
- **STREET 1:** 6749 BEN BOSTIC ROAD
- **CITY:** QUINCY
- **STATE:** FL
- **ZIP:** 32351

?xml version='1.0' encoding='ASCII'? tcnnf-20260129

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

____________________

**FORM 8-K**

___________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 29, 2026**

___________________

**TRULIEVE CANNABIS CORP.**

**(Exact Name of Registrant as specified in its charter)**

___________________

---

| | | |
|:---|:---|:---|
| **British Columbia** | **000-56248** | **84-2231905** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**3494 Martin Hurst Road Tallahassee, FL 32312 (Address of principal executive offices and zip code) (850) 298-8866**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Registrant's name or former address, if change since last report)** 

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. □

------

**Item 1.01&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement.**

***Overview***

On January 29, 2026, Trulieve Cannabis Corp. (the "Company") issued an additional U.S. $60 million aggregate principal amount of its 10.5% senior secured notes due December 17, 2030 (the "Additional Notes"). The Additional Notes were issued at a price of U.S. $1,000 plus accrued but unpaid interest from December 17, 2025 to January 29, 2026 in the amount of U.S. $12.37 per U.S. $1,000 principal of Additional Notes. Other than the issue price, the Additional Notes have identical terms as the U.S. $140 million aggregate principal amount of the Company's 10.5% senior secured notes due 2030 issued on December 17, 2025 (the "Original Notes" and, together with the Additional Notes, the "Notes"). The outstanding aggregate principal amount of the Notes, after the issuance of the Additional Notes, is U.S. $200 million.

The Notes were issued pursuant to a trust indenture dated as of June 18, 2019 (the "Base Indenture"), as supplemented by a supplemental trust indenture dated as of October 6, 2021 (the "Supplemental Indenture"), as supplemented by a second supplemental trust indenture dated as of December 17, 2025 (the "Second Supplemental Indenture" and, the Base Indenture as supplemented by the Supplemental Indenture and by the Second Supplemental Indenture, the "Indenture"), by and between the Company and Odyssey Trust Company, as trustee (the "Trustee").

The Notes bear interest at a rate of 10.5% per annum, payable semi-annually in arrears on June 17 and December 17 of each year after the date of issuance of the Notes, commencing on June 17, 2026 for the Additional Notes. Interest on the Notes will accrue from December 17, 2025. The Notes will mature on December 17, 2030, unless earlier redeemed or repurchased.

***Guarantees***

The obligations of the Company under the Indenture and the Notes have been irrevocably and unconditionally guaranteed, jointly and severally, by the Restricted Subsidiaries (as defined in the Indenture). As of January 29, 2026, the only Restricted Subsidiary was Trulieve, Inc. ("Trulieve US"). Trulieve US, its successors and assigns in any form, will remain Restricted Subsidiaries under the Indenture throughout the term of the Notes. Subject to certain conditions, the Chief Executive Officer and/or the Chief Financial Officer of the Issuer may at any time designate any Unrestricted Subsidiary to be a Restricted Subsidiary. A guarantor will be released from its obligations under its guarantee upon the occurrence of certain events.

***Ranking***

The Notes are direct senior secured obligations of the Company. Accordingly, the Notes are senior to all of the Company's existing and future unsecured indebtedness. The Notes are subordinated in right of payment only to any indebtedness that ranks senior to the Notes by operation of law.

***Security***

The Notes are secured solely by a pledge of the shares of Trulieve US.

***Optional Redemption***

At any time and from time to time prior to December 17, 2027, the Company may redeem all or part of the Notes, upon not less than 15 nor more than 60 days' prior notice, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus the applicable premium and accrued and unpaid interest on the outstanding principal amount of each Note called for redemption to the date of redemption.

At any time and from time to time on or after December 17, 2027, the Company may redeem all or part of the Notes, upon not less than 15 nor more than 60 days' prior notice, at a redemption price (expressed as percentages of the principal amount) set forth below plus accrued and unpaid interest to the applicable redemption date, of the years indicated below, subject to the rights of noteholders on the relevant record date to receive interest on the relevant payment date:

---

| | | |
|:---|:---|:---|
| Year | Percentage |  |
| December 17, 2027 to December 17, 2028 | 104 | % |
| December 17, 2028 to December 17, 2029 | 102 | % |
| December 17, 2029 and thereafter | 100 | % |

---

At any time prior to December 17, 2027, up to 35% of the Notes can be redeemed from the proceeds of a concurrent equity issuance at a redemption price of 108% plus accrued and unpaid interest on the outstanding principal amount of each Note called for redemption to the date of redemption.

***Change of Control***

In the event of a Change of Control (as defined in the Indenture), each holder will have the right to require that the Company purchase all or a portion of such holder's Notes at a purchase price in cash equal to 101% of the principal amount of such Notes plus accrued and unpaid interest, if any, to the date of purchase.

***Certain Covenants***

The Indenture contains covenants that, among other things, limit the ability of the Company and the Restricted Subsidiaries to:

•  declare or pay dividends or make certain other payments;

•  purchase, redeem or otherwise acquire or retire for value any equity interests or otherwise make any restricted payments;

•  conduct certain asset sales;

•  make certain restricted investments;

•  incur certain indebtedness;

•  grant certain liens;

•  enter into certain transactions with affiliates;

•  dispose of material permits; and

•  consolidate, merge or transfer all or substantially all of the assets of the Company and its subsidiaries on a consolidated basis.

These covenants are subject to a number of other limitations and exceptions as set forth in the Indenture.

***Events of Default***

The Indenture provides for events of default which, if certain of them occur, would permit the Trustee or the holders of at least 51% in aggregate principal amount of the then-outstanding Notes to declare the principal of, and interest or premium, if any, and any other monetary obligations on, all the then-outstanding Notes to be due and payable immediately.

The foregoing description of the Indenture and the Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Base Indenture, the Supplemental Indenture, the Second Supplemental Indenture, and the Notes, which are attached hereto as Exhibits 4.1, 4.2, 4.3 and 4.4, respectively, and incorporated by reference herein.

**Item 2.03&nbsp;&nbsp;&nbsp;&nbsp;Creation of a Direct Financial Obligations or an Obligation under Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

**Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;Other Events.**

On January 29, 2026, the Company issued a news release announcing the closing of the private placement of the Additional Notes. The Additional Notes, which were issued at a price of U.S. $1,000 plus accrued but unpaid interest from December 17, 2025 to January 29, 2026 in the amount of U.S. $12.37 per U.S. $1,000 principal of Additional Notes, are senior secured obligations of the Company. Other than the issue price, the Additional Notes have identical terms as Original Notes. The outstanding aggregate principal amount of the Notes, after the issuance of the Additional Notes, is U.S. $200 million.

The Company intends to use the net proceeds of the Offering for capital expenditures and other general corporate purposes.

The offering and sale of the Additional Notes have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or the laws of any other jurisdiction. This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, the Additional Notes, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

A copy of the press release announcing the Company's closing of the offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

------

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 4.1 | <u>[Trust Indenture, dated as of June 18, 2019, between Trulieve Cannabis Corp. and Odyssey Trust Company (incorporated by reference to Exhibit 4.7 to the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on January 12, 2021 (File No. 333-252052))](https://www.sec.gov/Archives/edgar/data/1754195/000119312521007334/d32577dex47.htm)</u> |
| 4.2 | <u>[Supplemental Trust Indenture, dated as of October 6, 2021, between Trulieve Cannabis Corp. and Odyssey Trust Company (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2021 (File No. 000-56248))](https://www.sec.gov/Archives/edgar/data/1754195/000119312521295642/d196830dex41.htm)</u> |
| 4.3 | <u>[Second Supplemental Indenture dated December 17, 2025 by and between Trulieve Cannabis Corp. and Odyssey Trust Company](https://www.sec.gov/Archives/edgar/data/1754195/000175419525000074/trulieveconformedsecondsup.htm)</u>(incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2025 (File No. 000-56248)) |
| 4.4 | Form of 2030 Note (included in Exhibit 4.3) |
| 99.1 | <u>[Press release dated January 29, 2026](trul_closingnotes2030x0129.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Trulieve Cannabis Corp. | Trulieve Cannabis Corp. |
| By: | /s/ Eric Powers |
| Name: | Eric Powers |
| Title: | Chief Legal Officer |

---

Date: January 29, 2026

## Exhibit 99.1

![image_0a.jpg](image_0a.jpg)

**Trulieve Announces Closing of US$60 Million Private Placement** 

**of 10.5% Senior Secured Notes**

**TALLAHASSEE, Fla. – January 29, 2026** – Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that, further to its December 17, 2025 news release, it has closed a second tranche of its previously announced private placement of 10.5% Senior Secured Notes due 2030 (the "Notes") in the principal amount of US$60.0 million (the "Offering"). Together with the first offering of Notes, which closed on December 17, 2025, Trulieve has issued Notes in the aggregate principal amount of US$200.0 million. The Notes were issued at a price of US$1,000 plus accrued but unpaid interest from December 17, 2025 to January 29, 2026 in the amount of US$12.37 per US$1,000 principal of Notes, and have the same terms as those issued on December 17, 2025.

The Offering was conducted on a "best-efforts" basis pursuant to the terms of an agency agreement, between the Company and Canaccord Genuity Corp., as sole agent and sole bookrunner. The Company will make the required filings to list the Notes on the Canadian Securities Exchange (the "CSE") following the expiry of the four-month Canadian statutory hold period.

The Company intends to use the net proceeds of the Offering for capital expenditures and other general corporate purposes.

The offering and sale of the Notes have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or the laws of any other jurisdiction. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

**Forward-Looking Statements**

This news release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to the Company's expectations or forecasts other plans, intentions, expectations, estimates, and beliefs and include statements regarding the proposed use of the net proceeds of the Offering, the listing of the Notes on the CSE and other matters. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current projections and expectations about future events and trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risks discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for

------

![image_0a.jpg](image_0a.jpg)

the year ended December 31, 2024 and in our periodic reports subsequently filed with the United States Securities and Exchange Commission and in the Company's filings on SEDAR+ at www.sedarplus.ca. There can be no assurance that any forward-looking information and statements herein will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise.

**About Trulieve**

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve <br>Instagram: @Trulieve<br>X: @Trulieve

**Investor and Media Contact**

Christine Hersey, Chief Corporate Affairs & Strategy Officer

+1 (424) 202-0210

Christine.Hersey@Trulieve.com

<br>